PMID- 22450893
OWN - NLM
STAT- MEDLINE
DCOM- 20120625
LR  - 20161125
IS  - 1531-7056 (Electronic)
IS  - 0267-1379 (Linking)
VI  - 28
IP  - 3
DP  - 2012 May
TI  - Drug-induced liver injury.
PG  - 198-202
LID - 10.1097/MOG.0b013e3283528b5d [doi]
AB  - PURPOSE OF REVIEW: Drug-induced liver injury (DILI) remains an important disease 
      in clinical practice. It is difficult to predict, diagnose and manage. Studies in 
      the peer-reviewed literature in the last 2 years, focusing on the diagnosis, 
      prediction and management of DILI will be reviewed. RECENT FINDINGS: Antibiotics 
      remain the most common drug causing DILI in the United States and Europe. Expert 
      opinion may still be the better method of diagnosing DILI compared with an 
      objective tool such as the Roussel-Uclaf Causality Assessment Method. Hepatitis E 
      represents an alternative diagnosis to some cases of presumed drug 
      hepatotoxicity. There is ongoing research into the genetics of the 
      pathophysiology and susceptibility of DILI. A genome-wide association study 
      confirmed the association between human leukocyte antigen (HLA) class II and 
      susceptibility to coamoxiclav (amoxicillin-clavulanic acid) induced DILI. There 
      is new information on the protective effect of HLA-DRB1*07 family of alleles. 
      MicroRNAs are a potential marker of DILI. Keratin variants may predict outcome of 
      acute liver failure. N-acetylcysteine may be protective against DILI while taking 
      antituberculosis medication. SUMMARY: Recent findings in the genetics of 
      pathophysiology and susceptibility of DILI can help with predicting and avoiding 
      DILI in clinical practice and provide the foundation for ongoing research.
FAU - Grant, Lafaine M
AU  - Grant LM
AD  - Division of Digestive and Liver Diseases, University of Texas Southwestern 
      Medical Center, Dallas, Texas 75390-8887, USA. Lafaine.grant@utsouthwestern.edu
FAU - Rockey, Don C
AU  - Rockey DC
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Gastroenterol
JT  - Current opinion in gastroenterology
JID - 8506887
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antitubercular Agents)
RN  - 0 (HLA-DRB1 Chains)
RN  - 0 (Protective Agents)
RN  - 74469-00-4 (Amoxicillin-Potassium Clavulanate Combination)
RN  - WYQ7N0BPYC (Acetylcysteine)
SB  - IM
MH  - Acetylcysteine/therapeutic use
MH  - Amoxicillin-Potassium Clavulanate Combination/adverse effects
MH  - Anti-Bacterial Agents/*adverse effects
MH  - Antitubercular Agents/adverse effects
MH  - *Chemical and Drug Induced Liver Injury/diagnosis/drug 
      therapy/epidemiology/physiopathology
MH  - Disease Susceptibility
MH  - Europe/epidemiology
MH  - Female
MH  - Genome-Wide Association Study
MH  - Genotype
MH  - HLA-DRB1 Chains
MH  - Humans
MH  - Male
MH  - Protective Agents/therapeutic use
MH  - Risk Factors
MH  - United States/epidemiology
EDAT- 2012/03/28 06:00
MHDA- 2012/06/26 06:00
CRDT- 2012/03/28 06:00
PHST- 2012/03/28 06:00 [entrez]
PHST- 2012/03/28 06:00 [pubmed]
PHST- 2012/06/26 06:00 [medline]
AID - 10.1097/MOG.0b013e3283528b5d [doi]
PST - ppublish
SO  - Curr Opin Gastroenterol. 2012 May;28(3):198-202. doi: 
      10.1097/MOG.0b013e3283528b5d.